From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 1991
Last Reported 2010
Negated 2
Speculated 1
Reported most in Abstract
Documents 4
Total Number 5
Disease Relevance 3.26
Pain Relevance 1.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Cacna1c) plasma membrane (Cacna1c) nucleus (Cacna1c)
transmembrane transport (Cacna1c) cytoplasm (Cacna1c)
Anatomy Link Frequency
4T1 1
brain 1
respiratory 1
Cacna1c (Mus musculus)
Pain Link Frequency Relevance Heat
nMDA receptor 7 97.52 Very High Very High Very High
opiate 2 97.40 Very High Very High Very High
depression 3 97.00 Very High Very High Very High
long-term potentiation 3 91.60 High High
Hippocampus 1 87.92 High High
palliative 1 81.44 Quite High
conotoxin 2 76.12 Quite High
medulla 1 75.76 Quite High
Glutamate 1 75.00 Quite High
agonist 2 73.16 Quite High
Disease Link Frequency Relevance Heat
Advanced Or Metastatic Breast Cancer 37 100.00 Very High Very High Very High
Cancer 24 98.72 Very High Very High Very High
Respiratory Failure 3 97.48 Very High Very High Very High
Bone Cancer 8 96.52 Very High Very High Very High
Breast Cancer 24 90.92 High High
Vomiting 2 90.00 High High
Multiple Myeloma 2 89.32 High High
Pressure And Volume Under Development 17 88.56 High High
Death 1 87.12 High High
Toxicity 8 85.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This study examined the effects of our lead compound, MBC-11 (the anhydride formed between arabinocytidine (AraC)-5'-phosphate and etidronate), on bone tumor burden, bone volume, femur bone mineral density (BMD), and overall survival using two distinct mouse models of TIBD, the 4T1/luc breast cancer and the KAS-6/1-MIP1alpha multiple myeloma models.
Spec (examined) Regulation (effects) of MBC-11 in 4T1 associated with breast cancer, multiple myeloma and bone cancer
1) Confidence 0.29 Published 2010 Journal Bone Section Abstract Doc Link 20233612 Disease Relevance 1.16 Pain Relevance 0.08
Radioligand binding studies revealed that the density of (+)[3H]isradipine binding sites in brain homogenates was reduced by 20-25% in CaV1.3 alpha 1(-/-) mice, without any detectable change in CaV1.2 (alpha 1C) protein levels as detected using Western blot analysis.
Neg (without) Regulation (change) of CaV1.2 in brain
2) Confidence 0.26 Published 2003 Journal Neuroscience Section Abstract Doc Link 12890513 Disease Relevance 0.26 Pain Relevance 0.42
They concluded that treatment with metronomic capecitabine and cyclophosphamide in combination with bevacizumab was effective in MBC and was minimally toxic.
Regulation (effective) of MBC associated with advanced or metastatic breast cancer
3) Confidence 0.17 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727886 Disease Relevance 1.44 Pain Relevance 0
On the other hand, L-type VDCC blockers are not protective.
Neg (not) Regulation (protective) of L-type VDCC
4) Confidence 0.05 Published 2005 Journal Mol. Pharmacol. Section Abstract Doc Link 16051748 Disease Relevance 0.15 Pain Relevance 0.50
Our results indicate that modulation of the L-type Ca2+ channels by dihydropyridines modifies sufentanil-induced respiratory depression at the controlling medullary mechanisms of breathing.
Regulation (modulation) of L-type in respiratory associated with depression and respiratory failure
5) Confidence 0.02 Published 1991 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1713849 Disease Relevance 0.26 Pain Relevance 0.46

General Comments

This test has worked.

Personal tools